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Abstract
Background. Japanese haemodialysis (HD) patients not
only have a very low mortality and hospitalization risk but
also low haemoglobin (Hb) levels. Internationally, anaemia
is associated with mortality, hospitalization and health-
related quality of life (QoL) measures of HD patients.
Methods. Longitudinal data collected from 1999 to 2006
from 60 to 64 representative Japanese dialysis units par-
ticipating in the Dialysis Outcomes and Practice Patterns
Study (DOPPS) were used to describe anaemia manage-
ment practices and outcomes for Japanese HD patients.
Results. From 1999 to 2006, patient mean Hb increased
from 9.7 g/dl to 10.4 g/dl, and the percentage of facilities
with median Hb ≥10 g/dl increased from 27% to 75%.
Hb was measured in the supine position for 90% of pa-
tients, resulting in substantially lower reported Hb values
than those seen in other countries. As of 2006, erythropoi-
etin (Epo) was prescribed to 83% of HD patients; mean
Epo dose was 5231 units/week; intravenous (IV) iron use
was 33% and median IV iron dose was 160 mg/month.
Many patient- and facility-level factors were significantly
related to higher Hb. A consistent overall pattern of lower
mortality risk with higher baseline Hb levels was seen
(RR = 0.89 per 1 g/dl higher Hb, P = 0.003). Facilities
with median Hb ≥10.4 displayed a lower mortality risk
(RR = 0.77, P = 0.03) versus facility median Hb
<10.4 g/dl. Lower Hb levels were not significantly related
to hospitalization risk, but were associated with lower QoL
scores.
Conclusions.Theseresultsprovidedetailedinformationon
anaemia management practices in Japan and the relation-
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ships of anaemia control with outcomes, with implications
of anaemia management worldwide.
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Introduction
The number of dialysis patients in Japan has reached
250 000 [1], and Japan’s prevalence of end-stage renal dis-
ease(ESRD)isoneofthehighestintheworld.Manystudies
haveshownthatdialysispatientsinJapanhavealowermor-
tality and hospitalization risk than dialysis patients in other
countries [2–4]. Several reasons for such a good progno-
sis among Japanese dialysis patients have been proposed,
such as long treatment time for dialysis [5], greater use
of arteriovenous fistulae for vascular access [6] and good
nutritional status of patients [7].
Management of anaemia is an important factor associ-
ated with prognoses such as mortality, hospitalization and
quality of life (QoL) in dialysis patients [8–10]. Japan’s
anaemia management stands in contrast to its low mortality
rates: Japan has the lowest haemoglobin (Hb) level of all
countries in the Dialysis Outcomes and Practice Patterns
Study (DOPPS) [10], which may be attributable to the low
dosages of erythropoietin (Epo) used in Japan and the in-
fluence of Japanese guidelines for treating renal anaemia
[11]. To further improve the outcomes of Japanese dialysis
patients, it is necessary to clarify the relationship between
anaemia and prognosis in Japanese patients. In this paper,
we examine DOPPS data on Japanese haemodialysis (HD)
patients from three phases of the study (1999–2006). We
describe many aspects of anaemia management practice
in Japan and investigate whether baseline Hb levels are
correlated with mortality, hospitalization and QoL of
C   The Author [2008].
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Japanese HD patients, as well as the relationship of pre-
dialysis Epo treatment with the subsequent mortality risk.
Methods
Data sources
Assessment of anaemia management in Japan and related
outcomes were based on data collected from randomly se-
lectedJapaneseHDunitsparticipatingintheDOPPS.These
dialysis units were selected to be nationally representative
of the various geographic regions in Japan, with 64 dial-
ysis units participating in DOPPS I (1999–2001), 60 dial-
ysis units in DOPPS II (2002–2004) and 61 facilities in
DOPPS III (2006). In DOPPS I, 56% of facilities were pri-
vate free-standing dialysis units, 42% were private hospital
units and 2% were private general hospital units. The rep-
resentation of dialysis units in DOPPS II was 43% from
private units, 28% private hospitals, 3% private general
hospitals, 3% private or national university hospitals and
22% official hospitals. The representation of dialysis units
in DOPPS III was very similar to that seen in DOPPS II.
At each participating dialysis unit, baseline data on de-
mographics,medicalhistory,laboratoryvalues,vascularac-
cess, anaemia measures, medications, vascular access and
patient QoL were collected at the time of patient entry
into the study. Thereafter, data on hospitalization, vascu-
lar access-related events, deaths and causes of death were
collected throughout the study; data on longitudinal labo-
ratory values and renal medication use were collected ap-
proximately every 4 months. Anaemia measures used for
analysis included patient Hb concentrations, haematocrit,
ferritin, transferrin saturation, iron, intravenous (IV) iron
use, type and dose of Epo preparation and frequency of
Epo administration. Nearly all DOPPS III data used for
analyses were obtained before the 1 April 2006 change in
the Japanese national policy for the reimbursement of Epo.
Additional details of the DOPPS sampling plan and study
methods have been previously described [12,13].
Statistical methods
Univariate analyses and t-tests were used to assess mean
values and statistical significance concerning differences
between groups. Logistic regression analysis was applied
to investigate patient factors associated with the likelihood
of having Hb >10.5 g/dl versus Hb ≤10.5 g/dl for patients
with ESRD >180 days. Logistic models were adjusted for
age, sex, body mass index (BMI), number of years with
ESRD, country, study phase, serum levels of calcium, albu-
min, phosphorus and iron, and 13 summary comorbid con-
ditions (coronary artery disease, congestive heart failure,
other cardiovascular disease, cerebrovascular disease, hy-
pertension, diabetes, peripheral vascular disease, recurrent
cellulitis/gangrene, lung disease, gastrointestinal bleeding
within the previous 12 months, neurologic disease, psychi-
atric disorder and cancer). Vascular access type in use at
study entry was found to be not significantly related to the
outcomes and therefore was not included as a model co-
variate in the results shown. All logistic regression models
used generalized estimating equations to account for clus-
tering at the facility level, assuming a compound symmetry
covariance structure. Mixed linear regression adjusted for
patientcharacteristicsandaccountingforfacilityclustering
effects was used to determine the relationship of Hb lev-
els among patients with various patient factors and facility
anaemia management practices.
Cox proportional hazards regression models were used
toexaminetherelationshipbetweenmortalityriskandapa-
tient’s baseline Hb concentration. Models were adjusted for
age, sex, BMI, years with ESRD, single-pool Kt/V, phos-
phorus,calcium,albumin,the13summarycomorbidcondi-
tions listed above and HIV/AIDS. Time at risk was defined
as the time from patient entry into DOPPS until death, de-
parture from the study or end of the study follow-up. The
patient mortality risk was also evaluated with relationship
to either the median Hb level of the patient’s dialysis facil-
ity or whether the patient’s dialysis facility had a median
Hb level ≥10.4 g/dl (the midpoint of the DOPPS III Hb
distribution in Japanese HD patients). Models using these
predictors of facility-level practices were adjusted for the
same factors as indicated above.
Cox models were also used to estimate the relationship
between patient Hb concentrations and time to first hospi-
talization during the study period due to cardiovascular-
related reasons, infection-related reasons or any cause.
Cardiovascular-related hospitalization was defined as hos-
pitalizationduetoorinvolvingacutemyocardialinfarction,
cardiac arrest, congestive heart failure, cardiomyopathy,
valvular heart disease, atrial fibrillation, other arrhythmia,
chest pain, hypertension, angina, cardiac catheterization,
coronary angioplasty, coronary bypass graft, valve repair
or replacement or cardioversion. Infection-related hospital-
ization was defined as hospitalization due to or involving
septicaemia, pneumonia, endocarditis, meningitis, celluli-
tis/soft tissue infection and osteomyelitis. Hospitalization
analyses were adjusted for the same factors used in mortal-
ity analyses. For the hospitalization analyses, time at risk
was defined as the time from patient entry into DOPPS
until first hospitalization event, departure from the study or
end of the study follow-up. All Cox models used a robust
estimator [14] to account for facility clustering.
Patient Hb concentrations were also related to patient
mental and physical component summary scores for QoL
(MCS, PCS), calculated from a standardized health-related
SF-36 questionnaire that patients completed soon after
study entry. Mixed linear regression was used to examine
the associations between Hb concentrations and MCS and
PCS scores. These models were adjusted for age, sex, years
with ESRD, albumin and the 14 summary comorbidities
noted above, and accounted for facility clustering effects.
AllanalyseswereperformedusingSASversion9.1(SAS
Institute, Cary, NC, USA) [15].
Results
The prevalence of selected patient comorbidities and other
characteristics was determined at the start of each DOPPS
phase covering the period from 1999 to 2006 (Table 1).
The mean age of Japanese HD patients increased by
3.7 years over this period, from a mean of 58.7 years inAnaemia and outcomes in Japanese HD patients: DOPPS 3645
Table 1. Prevalence of selected patient characteristics for Japanese patients in the DOPPS, by study phase (1999–2006)
DOPPS I (1999) DOPPS II (2002) DOPPS III (2006)
n = 2157 n = 1805 n = 1826
Mean age (years) (±SD) 58.7∗ (±12.4) 61.1∗ (±13.0) 62.4 (±12.5)
Male (%) 61.9 59.9 60.1
Mean years with end-stage renal disease 7.45∗ 7.06∗ 8.02
Mean body mass index (kg/m2)( ±SD) 20.4∗ (±2.86) 20.6∗ (±3.03) 21.0 (±3.21)
Diabetes as primary cause of ESRD (%) 22.6∗ 26.4∗ 30.1
Diabetes mellitus (any) (%) 25.8∗ 28.0∗ 32.4
Peripheral arterial disease (%) 11.5∗ 11.6∗ 17.3
Coronary artery disease (%) 19.5∗ 24.7∗ 28.3
Congestive heart failure (%) 6.2∗ 16.7∗ 25.4
Other cardiovascular disease (%) 24.1∗ 30.8 32.9
Hypertension (%) 56.4∗ 66.3∗ 72.9
Cerebrovascular disease (%) 12.6 14.4 13.4
Lung disease (%) 1.4∗ 2.3 2.6
Gastrointestinal bleeding in prior year (%) 3.7 4.4 4.0
Psychiatric disorder (%) 2.6 3.4 3.6
Neurologic disease (%) 4.0∗ 6.7∗ 10.0
Recurrent cellulitis/gangrene (%) 2.1∗ 3.4 4.0
History of cancer (%) 5.4∗ 6.2∗ 8.8
DOPPS, Dialysis Outcomes and Practice Patterns Study.
Results for each study phase based upon a prevalent cross-section of HD patients randomly selected for participation in DOPPS. Prevalence of
comorbidities in a cross-section of patients with ESRD >180 days was very similar to that shown for all patients in the table.
∗P < 0.05 for whether the DOPPS I or II value statistically differed from that of DOPPS III.
1999 to 62.4 years in 2006. Over the same period, the per-
centage of Japanese HD patients ≥75 years old rose from
11.1 to 17.8%, and the prevalence of diabetes mellitus and
hypertension increased by 25–30%. The prevalence of car-
diovasculardiseasealsorosesubstantially:congestiveheart
failurerosefourfold,andcoronaryarterydisease,peripheral
arterial disease and other cardiovascular disease all rose by
40–50%. The prevalence of cancer and neurologic disease
rosesignificantlytoo.Thus,thechangesinanaemiacontrol
inJapanfrom1999to2006shouldbeconsideredwithinthe
context of a patient population in which comorbidity bur-
den and the fraction of elderly patients rose considerably
over the same period.
Hb levels in Japanese HD patients, 1999–2006
The distribution of Hb concentrations was determined for
a prevalent cross-section of HD patients having chronic
renal failure >180 days at the beginning of each DOPPS
phase. As shown in Figure 1A, a substantial shift to higher
Hb levels occurred over the period: The mean patient Hb
concentrationrosefrom9.7g/dlin1999to10.4g/dlin2006
(P<0.0001).ThepercentageofJapaneseHDpatientswith
Hb ≥10 g/dl increased from 40% in 1999 to 65% in 2006.
Older HD patients were found to have considerably lower
mean Hb concentrations in DOPPS III, with patients of age
18–44 having mean Hb of 10.73 g/dl compared with 10.58,
10.32 and 10.15 for patients aged 45–60, 61–75 and >75
years, respectively. Although significantly higher mean Hb
levelswereobservedamongyoungerJapaneseHDpatients,
EpousewassignificantlygreateramongolderJapaneseHD
patients, ranging from 77 to 78% Epo use in patients 18–
60 years old versus 85% in 61–75 years old and 88% in
patients>75yearsold.Nosignificantdifferencesinweekly
Epo dose or IV iron use were seen across these age groups.
In DOPPS III, information was also collected regarding
the patient’s position when blood samples were drawn for
Hbmeasurement:91%ofpatientsweresupineand9%were
seated. For 90% of prevalent patients in the DOPPS III
cross-sectional sample, pre-dialysis session blood samples
were taken on Monday or Tuesday, similar to that seen in
DOPPS I and II (93%).
Anaemiacontrolwasalsoevaluatedasafacilitypractice.
Figure 1B shows the distribution of facility median Hb
levels in participating facilities by study phase. In 1999, a
bimodal distribution in the distribution of facility median
Hb levels was evident, with only 27% of Japanese facilities
having a median Hb concentration ≥10 g/dl. In contrast,
by 2006, 75% of Japanese units had achieved a median Hb
concentration ≥10 g/dl.
Multivariate logistic regression analyses (Table 2) were
used to determine the likelihood of patients in prevalent
cross-sections from each study phase to have Hb >10.5 g/
dl, the midpoint of the current recommended Hb target in
Japan. Patients who were male or who had higher albumin
or calcium levels were substantially more likely to have Hb
>10.5 g/dl. In addition, patients with higher phosphorus
or iron levels and patients with a higher BMI also dis-
played slightly higher odds of achieving Hb >10.5 g/dl,
although these relationships were significant in only some
ofthestudyphases.Incontrasttotheabovefactors,patients
who were older or had hypertension were significantly less
likely to have Hb >10.5 g/dl. However, we found no sig-
nificant differences in the likelihood of Hb >10.5 g/dl
for patients 18–44 years old versus older age categories.
Hypertensive patients were significantly less likely to
achieve Hb >10.5, though they had a 1.3-fold higher ad-
justed odds of being given Epo (P = 0.03); they did not
significantly differ from non-hypertensive patients in the
weekly Epo dose level. When the adjusted logistic model3646 T. Akizawa et al.
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Fig. 1. (A) Distribution of haemoglobin concentrations among preva-
lent Japanese haemodialysis patients with ESRD >180 days in DOPPS
I (1999), DOPPS II (2002) and DOPPS III (2006). The results for each
study phase are based upon a point-prevalent cross-section of HD patients
with ESRD >180 days in DOPPS I (n = 1996), DOPPS II (n = 1581)
or DOPPS III (n = 1656). The standard deviation ranged from 1.35 in
DOPPS I to 1.23–1.26 in DOPPS II and III. (B) Distribution of facil-
ity median haemoglobin concentrations among Japanese dialysis units in
DOPPS I (1999), DOPPS II (2002), and DOPPS III (2006). Facility me-
dian haemoglobin concentrations were determined for a point-prevalent
cross-section of HD patients having ESRD >180 days in each participat-
ing DOPPS dialysis unit at the start of each study phase; n = 64 facilities
for DOPPS I, n = 60 for DOPPS II and n = 61 for DOPPS III.
was repeated using a cut point of 10.0 g/dl for patients in
all DOPPS phases, the results obtained were very similar
to those using a cut point of 10.5 g/dl.
Erythropoietin use
Table 3 shows results on Epo use, IV iron use and iron sta-
tus. Epo was used by 83% of prevalent HD patients, with
99% of all such patients receiving it intravenously. The
Table 3. Trends in anaemia and iron management therapies and measures
for Japanese HD patients with ESRD >180 days, DOPPS II and III
DOPPS II
(2002)
DOPPS III
(2006)
n = 1634 n = 1695
Epo use (%) 83 83
Mean Epoa (units/week) 5176 5231
Median Epoa (units/week) 4500 4500
IV iron use (%) 32 33
Mean total IV iron given per 4 months (mg) b 424
Mean IV iron doses given per 4 months 11.7 10.9
% Patients for whom TSAT was reported 41 45
Mean (median) TSAT (%) (in facilities with
≥70% reporting of TSAT)
27 (25) 33 (26)
% Patients with TSAT<20% (in facilities with
≥70% reporting of TSAT)
33 31
% Patients for whom serum ferritin reported 61 71
Median serum ferritin (ng/ml) 122 86
% Patients with serum ferritin <50 ng/ml 27 36
% Patients with serum ferritin, 50–99 ng/ml 17 18
% Patients with serum ferritin, 100–499 ng/ml 39 37
% Patients with serum ferritin >499 ng/ml 17 9
DOPPS, Dialysis Outcomes and Practice Patterns Study.
Data for each study phase based upon a prevalent cross-section of HD
patients having ESRD>180 days.
aTo provide greater comparability between study phases, values >15 000
Epo units were excluded due to being far outside the typical distribution
resulting in one value deleted in DOPPS III data and 23 from DOPPS II.
The DOPPS II mean of 5598 Epo units/week was obtained without ex-
cluding Epo values. Median Epo dose values were unaffected by this
exclusion.
bDue to possible misinterpretation of study question, mean total IV iron
data collected in DOPPS II were not used for analyses.
Table 2. Adjusted odds ratio (AOR) of having Hb >10.5 g/dl (versus ≤ 10.5) for Japanese HD patients with ESRD >180 days, by DOPPS study phase
(1999–2006)
AOR (Hb > 10.5 versus ≤ 10.5)
Patient characteristic DOPPS (all phases) DOPPS I (1999) DOPPS II (2002) DOPPS III (2006)
(n = 4940) (n = 1811) (n = 1544) (n = 1585)
Male (versus female) 1.41∗∗ 1.55∗∗ 1.35∗ 1.35∗∗
Serum albumin (per 0.5 g/dl higher) 1.23∗∗ 1.30∗ 1.36∗∗ 1.26∗∗
Serum calcium (mg/dl) 1.13∗∗ 1.22∗∗ 1.21∗∗ 1.03
Serum phosphorus (mg/dl) 1.06∗∗ 1.07 1.07 1.04
Body mass index (per kg/m2)1 . 0 3 ∗ 1.05∗ 1.02 1.03
Serum iron (per 5 µg/dl higher) 1.02∗∗ 1.00 1.05∗∗ 1.02∗
Age (per 10 years older) 0.93∗ 0.99 0.99 0.88∗∗
Hypertension (yes versus no) 0.78∗∗ 0.67∗∗ 0.82 0.83
DOPPS, Dialysis Outcomes and Practice Patterns Study.
Results for each study phase are based on a prevalent cross-section of HD patients having ESRD>180 days; AORs were estimated using logistic models
that were adjusted for number of years with ESRD, coronary artery disease, congestive heart failure, other cardiovascular disease, cerebrovascular
disease, peripheral vascular disease, recurrent cellulitis/gangrene, diabetes, lung disease, GI bleed in prior year, neurologic disease, psychiatric disorder,
cancer, and accounted for facility clustering effects; all-phase analysis was also adjusted for study phase. For patient factors included in the model but
not shown in the table, no consistent significant relationship was seen with the odds of the patient having Hb >10.5 g/dl.
∗P = 0.01–0.05, ∗∗P < 0.01.Anaemia and outcomes in Japanese HD patients: DOPPS 3647
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Fig. 2. Epo dosing practices for Epo-treated HD patients in DOPPS III. (A) Distribution of facility mean Epo dose (Epo units/week) among DOPPS
III dialysis units. Facility mean Epo dose (units/week) was calculated based on the number of Epo units/week given to Epo-treated patients from
a point-prevalent cross-section of HD patients having ESRD >180 days in each participating DOPPS dialysis unit at the start of DOPPS III; n =
61 facilities. (B) Percentage of Epo-treated HD patients receiving one, two or three Epo doses per week in DOPPS III. Results are based upon a
point-prevalent cross-section of Japanese HD patients having ESRD >180 days at the start of DOPPS III; n = 1412 patients. (C) Distribution of
patient Epo doses (Epo units/week) in DOPPS III for patients receiving one, two or three Epo doses per week. Results are based on a point-prevalent
cross-section of Japanese HD patients having ESRD >180 days at the start of DOPPS III; n = 1412 patients.
average Epo dose given to Japanese prevalent HD patients
was 5176 units/week in DOPPS II and 5231 units/week
in DOPPS III. However, the facility mean weekly Epo
dose varied greatly across DOPPS III dialysis units
(Figure 2A): 53% of facilities provided a mean Epo dose
<5000 units/week, 24% a mean weekly dose of 5000–5999
units and 23% a mean weekly dose of 6000–9000 units.
Substantial variability was also seen in the number of
Epo doses given to patients per week (Figure 2B): 59%
of patients received three doses, 32% received two doses
and 10% received one dose. The Epo dosing patterns pro-
vided in Figure 2C display the most common weekly doses
of Epo administered to Japanese HD patients and demon-
stratetheverylargevariationinEpodosingstrategies,from
<2000 units/week to >9000 units/week.
Patient Hb concentrations were measured during the
same month during which Epo use was reported, and in-
dicated that, on average, patients with lower Hb levels were3648 T. Akizawa et al.
Fig. 3. (A) Distribution of facility IV iron use among Japanese dialysis
units in DOPPS I (1999), DOPPS II (2002) and DOPPS III (2006). The
percentage of patients within a facility using IV iron was determined for
a point-prevalent cross-section of HD patients having ESRD >180 days
in each participating DOPPS dialysis unit at the start of each study phase;
n = 63 facilities for DOPPS I, n = 60 for DOPPS II and n = 61 for
DOPPS III. (B) Distribution of the number of IV iron doses per month
given to prevalent HD patients in DOPPS III. Results are based on a point-
prevalent cross-section of Japanese HD patients having ESRD >180 days
at the start of DOPPS III; analyses were restricted to patients receiving IV
iron during the first month after study entry (n = 1336).
given a substantially greater average amount of Epo during
the 4-week period (2193 more units of Epo given during
4 weeks for every 1 g/dl lower Hb, P < 0.0001; adjusted
for demographics and 14 comorbidities, and restricted to
patients with ESRD >180 days). The following month’s
Hb value was found to rise significantly in proportion to
the amount of Epo given in the prior month (0.2 g/dl higher
Hb rise per 2500 units/week more Epo given during the
prior4-weekinterval,P<0.0001;adjustedfordemograph-
ics, 14 comorbidities, IV iron given in the prior 4 months,
and restricted to patients with ESRD >180 days). Over a
4-week period, most patients (∼90%) continued to receive
the same number of Epo doses from week to week, except
fornearly15%ofpatientswhowerereceivingoneEpodose
per week in the first study week and had their prescriptions
changed to two or three Epo doses per week by the fourth
week of the study.
Patients receiving one Epo dose for each of the 4 weeks
displayed an average decline of 0.33 g/dl in their mean
Hb over a subsequent 3- to 5-week period (P < 0.0001).
In contrast, patients receiving three Epo doses for each of
4 weeks displayed an average increase of 0.20 g/dl in their
mean Hb (P < 0.0001). There was essentially no change in
mean Hb over a 3- to 5-week period for patients receiving
two Epo doses for each of the 4 weeks in the month prior
to the second Hb measurement.
Intravenous iron use
Intravenous (IV) iron use remained relatively constant in
Japan, with 32% and 33% of prevalent HD patients re-
ceiving IV iron in 2002 and 2006, respectively (Table 3).
However, as shown in Figure 3A, a wide variation is seen
across Japanese dialysis units regarding the percentage of
patients within a facility receiving IV iron. In 2006, 33%
of Japanese dialysis facilities prescribed IV iron to <20%
of facility patients during a 4-month period; 29% of facili-
tiesprescribedIVironto≥50%ofpatientsduringthesame
period.
ThenumberofIVirondosesadministeredmonthlytopa-
tients varied greatly (Figure 3B). The median IV iron dose
given to prevalent HD patients in Japan was 160 mg/month
in DOPPS III, with ∼30% of iron recipients receiving
this amount of IV iron. For the remaining patients receiv-
ing IV iron, 17% each were given 40–60 mg/month, 80–
150 mg/month, 180–280 mg/month or 320–520 mg/month.
Three major forms of IV iron were being given to HD
patients in Japan in 2006: 46% of patients received sac-
charated ferric oxide (e.g. Fesin), 43% received a chon-
droitin sulfate/iron colloid mixture (e.g. Blutal) and 10%
received cideferron (e.g. Ferricon). The most common
IV iron dose amount was 40 mg/administration, given to
∼75% of Japanese HD patients receiving IV iron. Doses of
20 mg/administration were given to 6% of patients, and
doses of 50 mg/administration were given to 10% of pa-
tients; this last group mostly received cideferron.
Mean Hb concentrations were found to be significantly
higher in facilities administering IV iron to a larger frac-
tion of patients (Figure 4A). Across all facilities, mean Hb
concentrationswere0.067g/dlhigherforevery10%higher
facility use of IV iron (P = 0.007).
Iron management measures
Assessment of iron status was not routinely performed
for all HD patients in Japan on a regular basis. In a
point-prevalent cross-section of HD patients with ESRD
>180 days, transferrin saturation (TSAT) was reported for
only 41% and 45% of Japanese HD patients in DOPPS
II and III, respectively; ferritin was reported for 61% and
71% of patients in DOPPS II and III, respectively (Table 3).
However, Japanese facilities in DOPPS III differed greatly
in whether TSAT or ferritin was measured. For example,
both ferritin and TSAT were reported for ≥80% of patients
at39%ofJapanesedialysisunits.FerritinbutnotTSATwas
measured for ≥80% of patients at 21% of Japanese dialysis
units. In contrast, at 16% of facilities, both TSAT and fer-
ritin were measured for <20% of patients, with no TSAT,
transferrin iron binding capacity or ferritin measurements
reported for any patient in most of these facilities.
Multivariate regression analysis indicated that preva-
lent HD patients having TSAT <20% or with ferritin
>499 ng/ml had significantly lower mean Hb concen-
trations (Figure 4B). As in previous international results
from the DOPPS [10], higher ferritin concentrations wereAnaemia and outcomes in Japanese HD patients: DOPPS 3649
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Fig. 4. Iron management and patient haemoglobin levels in DOPPS
II and III. (A) Percentage of facility patients receiving IV iron and
the mean haemoglobin concentration in Japanese HD patients having
ESRD >180 days. The association between facility IV iron use and
patient Hb levels was estimated using mixed linear regression models
adjusted for age, sex, years with ESRD, coronary artery disease, conges-
tive heart failure, other cardiovascular disease, cerebrovascular disease,
peripheral vascular disease, hypertension, recurrent cellulitis/gangrene,
diabetes, lung disease, GI bleed in prior year, neurologic disease, psy-
chiatric disorder, cancer, HIV and albumin. Facility IV iron use was
calculated as the percentage of IV iron use in a cross-section of fa-
cility HD patients having ESRD >180 days in DOPPS II and III
(n=2850).(B)Differenceinthemeanhaemoglobinconcentrationamong
patients by levels of ferritin (n = 3244) and percent transferrin saturation
(TSAT) (n = 2850). The relationship was estimated using mixed linear
regression models with the patient haemoglobin level as the outcome, ad-
justing for the same factors as in (A), as well as calcium, phosphorus and
BMI. Results are based on a prevalent cross-section of DOPPS II and III
HD patients having ESRD >180 days at the time of study initiation.
related to lower Hb concentrations across most of the fer-
ritin concentration range.
Association of patient Hb levels with mortality risk,
hospitalization risk and QoL
Crude mortality rates were observed to be higher in pa-
tients with lower baseline Hb levels ranging from 10.2%
for patients with Hb <8 g/dl to 7.2% with Hb 8–9 g/dl and
5.0%–5.3% for Hb levels >9 g/dl. In multivariate analyses
adjusted for numerous patient characteristics and labora-
tory values, higher baseline Hb levels were associated with
a lower overall mortality risk when data from DOPPS I,
II and III were combined: the relative risk (RR) of death
was 11% lower for every 1 g/dl higher Hb concentration
(P = 0.003) when all patient Hb values were considered
(Figure 5). Although the mortality risk was consistently
seen to be lower for patients with higher Hb levels, mor-
tality risk was especially high for patients with Hb <8g / d l
(RR = 1.78, P = 0.006 versus Hb 11–12 g/dl). For patients
with baseline Hb ≥8 g/dl, a 6% lower mortality risk was
observed for every 1 g/dl higher Hb (P = 0.20). The mor-
tality risk did not significantly differ for patients with Hb
8–11 g/dl or >12 g/dl compared to patients with Hb 11–
12 g/dl.
Hb control was also analysed as a facility practice. A
trend towards the lower mortality risk was observed for
patients treated in facilities having higher median Hb lev-
els, although this overall relationship did not reach statis-
tical significance in the fully adjusted Cox models (RR =
0.91 per 1 g/dl higher facility median Hb concentration,
P = 0.24). However, patients treated in facilities with a me-
dian Hb concentration equal to or greater than the DOPPS
III mean of 10.4 g/dl (n = 1381) displayed a 23% lower
mortality risk (P = 0.03) than patients in facilities having
a median Hb concentration <10.4 g/dl (n = 4017) in Cox
models with full adjustment. In a separate analysis, no sig-
nificant relationship was observed between the change in
the country mean Hb level and country mortality rate in
Japan from 1999 to 2006 (results not shown).
Data from a Japanese cohort of patients new to ESRD
were analysed to determine the mean Hb level for patients
when initiating HD, and how the level changed during the
first year of HD. Patients initiated HD with a low mean Hb
concentrationof8.3g/dl,suggestingpooranaemiamanage-
ment before the onset of ESRD (Figure 6). Within 1.5–3
months of beginning HD, >90% of these incident HD pa-
tients were given Epo; the mean Hb level of this incident
patient cohort rose from 8.3 g/dl to 10.5 g/dl within 3–5
months after beginning HD. Among Japanese patients en-
tering DOPPS within 90 days of ESRD onset, the risk of
mortality was significantly lower for patients who had re-
ceived Epo before beginning HD (RR = 0.51, P = 0.04)
than for those not receiving Epo, after adjusting for age,
sex, race, time since ESRD onset, 14 comorbidities, facil-
ity clustering effects and whether the patient had been seen
by a nephrologist >30 days before ESRD onset (N = 918).
Nosignificantassociationwasobservedbetweenapatient’s
baseline Hb concentration and risk of all-cause hospital-
ization, cardiovascular-related hospitalization or infection-
related hospitalization.
An assessment was performed to determine the relation-
shipofpatientHblevelswithQoL,asmeasuredbythePCS
andMCSscoresoftheKDQOLSF-36surveycompletedby
patients at study entry. The PCS score was nearly 1.6 points
lower for patients with Hb <8 g/dl than for patients with
Hb 11–12 g/dl (P = 0.02). These results suggest that se-
vere anaemia was associated with decreased physical func-
tioning of Japanese HD patients. Similarly, the MCS score
was 1.6 points lower for patients with Hb <8 g/dl versus3650 T. Akizawa et al.
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Hb 11–12 g/dl, but this difference did not reach statistical
significance (P = 0.07).
Discussion
Japan not only has the lowest HD patient mortality rate
amongthe12countriesparticipatingintheDOPPS[2,3,16]
but also displays the most conservative anaemia manage-
ment program for HD patients among these 12 countries.
Anaemia management practices observed in Japan should
be considered in the context of Japanese anaemia manage-
ment guidelines for HD patients. From 1990 through 2003,
a haematocrit of 30% (Hb ∼10 g/dl) was generally recom-
mendedasagoalforHDpatientstreatedwithEpo.In2004,
the first anaemia management guidelines for Japanese HD
patientswereproposedbytheJapaneseSocietyforDialysis
Therapy (JSDT), which recommended a target Hb level of
10–11 g/dl for most chronic Japanese HD patients when
measured at the first dialysis session of the week [11]. A
higher Hb target of 11–12 g/dl was recommended for rela-
tively young patients.
For ∼90% of HD patients in Japan, Hb measurements
are taken while patients are in a supine position, and for
∼80% of patients, blood samples are taken during the first
dialysis session of the week. In 2001, Inagaki et al. [17]
reported haematocrit levels to be 7–8% higher (P < 0.01)
for HD patients placed in a supine position for 5 versus
30 min. Gejyo et al. [11] showed that mean Hb levels
were 10.7 g/dl when blood samples were taken in a seatedAnaemia and outcomes in Japanese HD patients: DOPPS 3651
position versus 10.1 g/dl when taken shortly thereafter in a
supineposition,among99JapaneseHDpatients.Similarly,
Jacob et al. [18] studied 28 healthy subjects, observing that
overall haematocrit was 11% higher in a standing versus
supine position (37.7% versus 41.8%) and plasma volume
was17.9%lowerinastandingversussupineposition.These
results are consistent with prior studies showing a 10–18%
change in plasma volume in response to switching from
a supine to upright posture [19–22], and with the under-
lying mechanism that standing up causes a net movement
of fluid from intravascular to interstitial spaces, resulting
in a decrease in plasma volume, and higher haematocrit
percentages. Separately, Hb levels measured on the first
dialysis session of the week have been seen to be slightly
lower than Hb levels measured during mid-week dialysis
sessions [11]. Taken together, these common practices of
measuringHblevelsofJapaneseHDpatientsresultinlower
reported Hb values than would be obtained in most other
countries for the same level of anaemia control, since most
other countries commonly measure Hb levels in a seated
position during a mid-week dialysis session. An extrapola-
tion from the JSDT anaemia guideline paper [11] suggests
that a target of 10–11 g/dl in Japan may be equivalent to
a target of ∼10.7–11.7 g/dl in another country measuring
Hb levels in a seated position and during a mid-week ses-
sion. Considering the substantial effect of blood sampling
posture on observed Hb or haematocrit levels, an impor-
tant consideration for future guideline recommendations
would be to address this issue as part of anaemia manage-
ment of patients receiving dialysis in supine versus upright
positions.
Over the last 10 years, mean Hb levels have risen
in many countries following the publication of new
evidence-based guidelines for anaemia management that
have recommended higher Hb levels for HD patients.
This observation suggests that published guidelines and
the guideline-related clinical discussions that typically fol-
low guideline publication play substantial roles in affect-
ing changes in practice and country mean Hb levels. The
mean Hb levels observed in Japan from 1999 to 2006 align
well with the recommended Hb targets at each time point,
suggesting that these targets and possibly others may play
an important role in stimulating the large improvement in
anaemia control seen in Japan over this period. The mean
Hb concentration among Japanese HD patients increased
from 9.7 g/dl in 1999 to 10.4 g/dl in 2006. However, be-
cause of the blood sampling practices discussed above, the
mean Hb concentration of 10.4 g/dl for Japanese patients
may be equivalent to ∼11.1 g/dl for patients in a seated
position during a mid-week dialysis session.
Even with a mean Hb concentration as high as 11.1 g/dl,
the level of anaemia control is considerably lower in Japan
than in most other DOPPS countries. Practice guidelines
may contribute to the disparities between Hb attainment
in Japan and other countries, although this is difficult to
quantify. Nonetheless, there is considerable global debate
regarding what is the best target Hb range for HD patients.
In deciding upon the Hb target range for chronic HD pa-
tients in Japan, the JSDT [11] cited four main pieces of
evidence: lower mean Hb levels in the general population
in Japan compared with those in the US and Europe; results
from a JSDT statistical survey and the work of Hirasawa
et al. [23] showing a haematocrit level of 30–33% to be
associated with the lowest mortality risk in Japanese HD
patients; additional JSDT results showing the lowest mor-
tality risk for patients aged 35–45 years to be observed at
haematocrit33–36%,andhaematocrit30.8–33.6%inJapan
being nearly equivalent to 33–36% in Europe and the USA
because of differences in method and timing of blood sam-
ple collection. In making its recommendations in 2004, the
JSDT indicated the need to regularly review outcomes as-
sociated with different levels of anaemia control and the
need for a large-scale prospective randomized clinical trial
in the future to help further define the ideal Hb target range
for chronic HD patients.
The rise in mean Hb in Japanese HD patients from 1999
to 2006 occurred broadly across Japan, with the percent-
age of facilities having median Hb ≥10 g/dl rising from
27% in 1999 to 75% in 2006. A relatively conservative
anaemia management practice is seen for HD patients in
Japan, employing an average weekly mean Epo dose of
5000–5500 units/week, with 32–33% of patients given IV
iron during a 4-month period and receiving an average of
∼425 mg iron per 4-month period. However, as of early
2006, 35% of Japanese HD patients had Hb values below
the recommended target minimum of 10 g/dl. We speculate
that this finding may reflect non-adherence to the anaemia
guideline, the Japanese policy restricting reimbursement to
9000 Epo units/week, and the packaging recommendation
of 4500–6000 Epo units/week for maintenance doses.
Current anaemia management practices in Japan have
resulted in substantially lower mean Hb levels for older
HD patients. In contrast, very little difference in mean Hb
concentrations is seen across age groups in other countries
participating in DOPPS III (data not shown). The observed
differences in anaemia control with older patients in Japan
appear to be a result of anaemia management practices
rather than age-related biological limitations.
Logistic regression analyses were used to examine the
likelihood of Japanese HD patients achieving Hb of at least
10.5 g/dl, the midpoint of the current recommended target
range. The results of these analyses suggest that two of the
mostimportantfacilitypracticesforachievingthisHblevel
aregivingIVirontoahigherpercentageofpatientsandpro-
viding a higher weekly dose of Epo. Indeed, facilities with
greater IV iron use exhibited significantly higher mean Hb
levels, and patients who were given three Epo doses per
week displayed a significant and substantial rise in Hb lev-
els in the subsequent month, compared with a decline or
no change in mean Hb levels for patients receiving one or
two Epo doses per week. Another important factor revealed
by these analyses was that a higher level of anaemia con-
trol was consistently seen for Japanese patients having high
albumin levels but not high ferritin levels. High albumin
levels often serve as an indicator of good nutritional status
in the absence of underlying inflammation. Other DOPPS
analyses have shown that Japanese HD patients display the
highest mean creatinine concentration and the lowest per-
centage of patients with a diagnosis of malnourishment
among the 12 DOPPS countries [24], providing additional
evidence of good nutritional care for HD patients in Japan.
This level of nutritional care may be another reason for the3652 T. Akizawa et al.
ability of Japanese patients to attain higher Hb levels with
relatively low doses of Epo.
In 2004, Pisoni et al. [10] described country variations
in anaemia management indicators and practices across the
12 countries in the DOPPS. Those comparisons indicated
that for nearly all measures, all other DOPPS countries
achievedahigherlevelofanaemiacontrolthanJapan(rang-
ing from 11.1 g/dl in France to 12.0 g/dl in Sweden). That
study found IV iron use ranging from 53% in Italy to 89%
in Belgium, Epo use ranging from 83% in France to 94%
in the UK, Belgium and Sweden and mean weekly Epo
doses ranging from 6846 in Germany to 17 360 in the
USA. In contrasting the anaemia management practices in
Japan with that of other countries, it is important to con-
sider that Japan has the highest use of native arteriovenous
fistulae (∼91%) and lowest use of central vein catheters
(1%–2%) among all countries in the DOPPS. Since the risk
of infection and inflammation isknown tobe strongly asso-
ciated with catheter use [25] and catheter use is associated
with lower Hb levels [10], this much lower use of catheters
in Japan would be expected to decrease the exposure of
Japanese patients to sources of inflammation, thereby sup-
porting better anaemia control. As partial confirmation of
this relationship, an evaluation of DOPPS II data revealed
a much lower occurrence of septicaemia among HD pa-
tients in Japan versus those in any other DOPPS country (T
Kawaguchi and RL Pisoni, work in progress).
Anaemia is a key factor associated with mortality of
dialysis patients, and its importance has been pointed out
in many studies [8–10,26,27]. Japan exhibits the lowest
mean maintenance Hb level—but also the lowest mortality
risk for HD patients—among the 12 DOPPS countries [2].
Even in Japan with its low mortality risk, anaemia is signif-
icantly associated with mortality, as shown by the overall
lower mortality risk of RR = 0.89 (P = 0.003) for every
1 g/dl higher Hb level. Patients with baseline Hb <8g / d l
displayed a significantly higher mortality risk (RR = 1.78)
than patients with Hb 11–12 g/dl. We found no significant
differenceinmortalityriskforgroupsatdifferentHblevels.
Thisresultmaybeattributabletotheverylowmortalityrisk
of Japanese dialysis patients and to the limited number of
patients in each Hb group. However, the possibility of con-
founding by indication isinherent inpatient-based analyses
of observational data. This potential confounding makes it
difficult to interpret how much of the observed mortality
risk can be attributed to Hb levels per se and how much
reflects the health status of sicker patients who have lower
Hb levels arising from unmeasured comorbid conditions.
In order to minimize the confounding by indication bias as-
sociated with patient-level analyses, the DOPPS was one of
the first to publish a large, multi-centre facility-based find-
ing indicating that patients displayed a significantly lower
mortality risk if treated in facilities where a larger percent-
age of patients had Hb ≥11 g/dl [10]. This facility-based
observation has been supported subsequently by Wolfe
et al. [28], who showed significantly lower standardized
mortality ratios in nearly 3000 US dialysis facilities having
a higher percentage of patients with haematocrit ≥33%.
These authors also showed that US facilities that had in-
creased the fraction of patients with haematocrit ≥33%
over a 4-year period displayed significant improvements in
patient longevity over the same period. These results do
not necessarily conflict with the findings from the CHOIR
randomized trial [29], which showed a strong trend to-
wards higher mortality risks for HD patients targeted to
Hb 13.5 versus 11.3 g/dl, since the points of reference for
the mortality comparisons differed considerably in the two
studies.
Our observation of a 23% lower RR of death in facili-
ties with mean Hb >10.4 g/dl (compared to facilities with
mean Hb ≤10.4 g/dl) suggests a possible survival benefit
for Japanese dialysis patients through the improvement of
anaemia. A particular strength of this facility-based analy-
sisisthatithelpsreducethebiasbyindicationthatcanexist
inpatient-basedanalyses.Thefacility-basedresultprovides
insight into how the mortality risk for patients at a facility
is related to the facility’s Hb management practices rather
than being related to the Hb level of a particular patient.
We observed no significant relationship between the
change in Japan’s mean Hb level and mortality rate from
1999 to 2006. However, there has been a substantial in-
crease in the mean patient age and in the comorbidity
burden among Japanese HD patients over this time period
(Table 1). Other practices may also have changed over this
same period and exerted detrimental effects; the lack of
correlation between the change in Hb control and country
HD patient mortality rate does not exclude the possibility
thatimprovementsinanaemiacontrolhavehadabeneficial
effect.
Hospitalization risk was not markedly associated with
Hb levels. Although the incidence of hospitalization of HD
patients is lower in Japan than in any other DOPPS coun-
try, the percentage of patients hospitalized for non-medical
reasons (such as social reasons) was the highest in Japan,
which may modify the effect of Hb levels [2].
Anaemia is an important determinant factor for QoL,
which is closely associated with mortality and hospitaliza-
tion risk [30,31]. It has been reported that Japanese dialysis
patientshavehighPCSscorescomparedwithotherDOPPS
countries, but lower MCS scores than the USA [32]. Our
study showed that patients with severe anaemia had signif-
icantly lower PCS scores, raising the question of whether
poorer anaemia control may lead to lower PCS scores, or
vice versa. The impact of anaemia control on PCS is par-
ticularly relevant considering the prior work showing PCS
scores to be more strongly associated with HD patient mor-
tality risk than a patient’s albumin concentration [31].
Conclusion
This study provides a detailed description of anaemia man-
agement practices for HD patients in Japan, and relation-
ships with outcomes. The anaemia management practices
implemented in Japan provide an important perspective
for assessing outcomes obtained through different anaemia
management approaches worldwide. A large improvement
in anaemia management has been seen in Japan from 1999
to 2006. However, on average, Hb levels in Japanese HD
patients are low compared with those seen in other DOPPS
regions.Anaemia and outcomes in Japanese HD patients: DOPPS 3653
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